Similarly, CLL patient serum contains elevated levels of BAT3 (NKp30 ligand), HLA-E (NKG2A ligand), HLA-G (ILT2/KIR2DL4 ligand), and Gal-9 (TIM3 ligand)—these soluble ligands have all been demonstrated to have NK-inhibitory effects [97,103,121,128,135,143,144,145,146]. This evidence concerns the gene LILRB1 and B-cell chronic lymphocytic leukemia.